Hims & Hers defended at BofA as Lilly fights compounded GLP-1s [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
America on Thursday defended Hims & Hers Health ( NYSE: HIMS ), which recently announced a similar product line and sold off on the news. Last month, the San Francisco, California-based telehealth platform launched compounded GLP-1s containing semaglutide, the active pharmaceutical ingredient of Novo Nordisk's ( NVO ) popular weight loss drugs Ozempic and Wegovy, at a sharp discount to branded products. On Thursday, Lilly ( LLY ) filed additional lawsuits against business entities selling compounded versions of tirzepatide, falsely referring to their products as Mounjaro and Zepbound, its FDA-approved diabetes/weight loss drugs. While HIMS expects to launch compounded tirzepatide within the next few months, BofA analyst Allen Lutz said he doesn't think the company is making misleading claims about its GLP-1 products. “Looking at HIMS' website, the company does not appear to make misleading claims about the facilities within which the compounded products are manufactured or the
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- Hims & Hers offers compounded Wegovy for $99 a month to select professions [Yahoo! Finance]Yahoo! Finance
- Hims & Hers offers compounded Wegovy for $99 a month to select professions [Yahoo! Finance]Yahoo! Finance
- Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First RespondersBusiness Wire
- 3 US Insider Picks With Earnings Growth Up To 98% [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 8/5/24 - Beat
HIMS
Sec Filings
- 9/23/24 - Form 4
- 9/23/24 - Form 4
- 9/20/24 - Form 144
- HIMS's page on the SEC website